All In Biotech

Drug Trial Radar · NCT06790394

Test-retest Study With [18F]FBB in Cardiac Amyloidosis

A Test-retest Study to Evaluate the Reproducibility of [18F]Florbetaben PET Imaging in Patients With Cardiac Amyloidosis and Control Patients

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Oct 21, 2025

Primary completion

Oct 7, 2026

Study completion Oct 7, 2026

Sponsor

Lead sponsor
Lantheus Germany GmbHIndustry
Sponsor type
Industry
Collaborators
pharmtrace
First posted
Jan 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label study to evaluate and characterize test-retest reliability of \[18F\]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the \[18F\]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of \[18F\]florbetaben uptake in the heart will be performed.

Conditions

  • Cardiac Amyloidosis

Interventions

  • Florbetaben F18Drug

    Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Test-Retest variability of cardiac [18F]florbetaben PET uptakeTime frame: The duration of the study for participants may be up to 73 days.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Free Hospital

    London, United Kingdom

  • King's College London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.